MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features

References

1. 1.↵
   2. Stupp R,
   3. Mason WP,
   4. van den Bent MJ, et al

   ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96 doi:10.1056/NEJMoa043330 pmid:15758009

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Hegi ME,
   3. Diserens AC,
   4. Gorlia T, et al

   . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003 doi:10.1056/NEJMoa043331 pmid:15758010

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Brandes AA,
   3. Franceschi E,
   4. Tosoni A, et al

   . O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol 2010;12:283–88 doi:10.1093/neuonc/nop050 pmid:20167816

   CrossRefPubMed
4. 4.↵
   2. Gupta K,
   3. Salunke P

   . Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol 2012;138:1971–81 doi:10.1007/s00432-012-1323-y pmid:23052697

   CrossRefPubMed
5. 5.↵
   2. Kong DS,
   3. Kim ST,
   4. Kim EH, et al

   . Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382–87 doi:10.3174/ajnr.A2286 pmid:21252041

   Abstract/FREE Full Text
6. 6.↵
   2. Jung TY,
   3. Jung S,
   4. Moon KS, et al

   . Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep 2010;23:1269–76 doi:10.3892/or_00000760 pmid:20372840

   CrossRefPubMed
7. 7.↵
   2. Brandes AA,
   3. Franceschi E,
   4. Paccapelo A, et al

   . Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications. Oncologist. 2017;22:432–37 doi:10.1634/theoncologist.2016-0254 pmid:28275120

   Abstract/FREE Full Text
8. 8.↵
   2. Johnson BE,
   3. Mazor T,
   4. Hong C, et al

   . Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343:189–93 doi:10.1126/science.1239947 pmid:24336570

   Abstract/FREE Full Text
9. 9.↵
   2. Park CK,
   3. Kim JE,
   4. Kim JY, et al

   . The changes in MGMT promoter methylation status in initial and recurrent glioblastomas. Transl Oncol 2012;5:393–97 doi:10.1593/tlo.12253 pmid:23066447

   CrossRefPubMed
10. 10.↵
    2. Moon WJ,
    3. Choi JW,
    4. Roh HG, et al

    . Imaging parameters of high-grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology 2012;54:555–63 doi:10.1007/s00234-011-0947-y pmid:21833736

    CrossRefPubMed
11. 11.↵
    2. Sunwoo L,
    3. Choi SH,
    4. Park CK, et al

    . Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme. J Magn Reson Imaging 2013;37:351–58 doi:10.1002/jmri.23838 pmid:23023975

    CrossRefPubMed
12. 12.↵
    2. Choi YS,
    3. Ahn SS,
    4. Kim DW, et al

    . Incremental prognostic value of ADC histogram analysis over MGMT promoter methylation status in patients with glioblastoma. Radiology 2016;281:175–84 doi:10.1148/radiol.2016151913 pmid:7120357

    CrossRefPubMed
13. 13.↵
    2. Ryoo I,
    3. Choi SH,
    4. Kim JH, et al

    . Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles. PLoS One 2013;8:e71704 doi:10.1371/journal.pone.0071704 pmid:23977117

    CrossRefPubMed
14. 14.↵
    2. McGirt MJ,
    3. Chaichana KL,
    4. Gathinji M, et al

    . Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009;110:156–62 doi:10.3171/2008.4.17536 pmid:18847342

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Rosen BR,
    3. Belliveau JW,
    4. Vevea JM, et al

    . Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249–65 doi:10.1002/mrm.1910140211 pmid:2345506

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Ostergaard L,
    3. Sorensen AG,
    4. Kwong KK, et al

    . High resolution measurement of cerebral blood flow using intravascular tracer bolus passages, Part II: experimental comparison and preliminary results. Magn Reson Med 1996;36:726–36 doi:10.1002/mrm.1910360511 pmid:8916023

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Wetzel SG,
    3. Cha S,
    4. Johnson G, et al

    . Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803 doi:10.1148/radiol.2243011014 pmid:12202717

    CrossRefPubMedWeb of Science
18. 18.↵
    The National Cancer Institute Web site. Wiki for the VASARI feature set. Updated May 25, 2015. https://wiki.cancerimagingarchive.net/display/Public/VASARI+Research+Project. Accessed June 1, 2016
19. 19.↵
    2. Gerson SL

    . MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296–307 doi:10.1038/nrc1319 pmid:15057289

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Preusser M

    . MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol 2009;24:511–18 doi:10.14670/HH-24.511 pmid:19224454

    CrossRefPubMed
21. 21.↵
    2. Storey K,
    3. Leder K,
    4. Hawkins-Daarud A, et al

    . Glioblastoma recurrence and the role of O(6)-methylguanine-DNA methyltransferase promoter methylation. JCO Clin Cancer Inform 2019;3:1–12 doi:10.1200/CCI.18.00062 pmid:30758983

    CrossRefPubMed
22. 22.↵
    2. Feldheim J,
    3. Kessler AF,
    4. Monoranu CM, et al

    . Changes of O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation in glioblastoma relapse: a meta-analysis type literature review. Cancers (Basel) 2019;11:1837 doi:10.3390/cancers11121837 pmid:31766430

    CrossRefPubMed
23. 23.↵
    2. Ellingson BM,
    3. Cloughesy TF,
    4. Pope WB, et al

    . Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroiimage 2012;59:908–16 doi:10.1016/j.neuroimage.2011.09.076 pmid:22001163

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Han Y,
    3. Yan LF,
    4. Wang XB, et al

    . Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. BMC Cancer 2018;18:215 doi:10.1186/s12885-018-4114-2 pmid:29467012

    CrossRefPubMed
25. 25.↵
    2. Suh CH,
    3. Kim HS,
    4. Jung SC, et al

    . Clinically relevant imaging features for MGMT promoter methylation in multiple glioblastoma studies: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2018;39:1439–45 doi:10.3174/ajnr.A5711 pmid:30002055

    Abstract/FREE Full Text
26. 26.↵
    2. Smits M,
    3. van den Bent MJ

    . Imaging correlates of adult glioma genotypes. Radiology 2017;284:316–31 doi:10.1148/radiol.2017151930 pmid:28723281

    CrossRefPubMed
27. 27.↵
    2. Rundle-Thiele D,
    3. Day B,
    4. Stringer B, et al

    . Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. J Med Radiat Sci 2015;62:92–98 doi:10.1002/jmrs.103 pmid:26229673

    CrossRefPubMed
28. 28.↵
    2. Romano A,
    3. Calabria LF,
    4. Tavanti F, et al

    . Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Eur Radiol 2013;23:513–20 doi:10.1007/s00330-012-2601-4 pmid:22875158

    CrossRefPubMed
29. 29.↵
    2. Kotrotsou A,
    3. Elakkad A,
    4. Sun J, et al

    . Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. J Neurooncol 2018;139:125–33 doi:10.1007/s11060-018-2850-4 pmid:29619649

    CrossRefPubMed
30. 30.↵
    2. Stummer W,
    3. Pichlmeier U,
    4. Meinel T, et al

    . Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre Phase III trial. Lancet Oncol 2006;7:392–401 doi:10.1016/S1470-2045(06)70665-9 pmid:16648043

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Idoate MA,
    3. Diez Valle R,
    4. Echeveste J, et al

    . Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. Neuropathology 2011;31:575–82 doi:10.1111/j.1440-1789.2011.01202.x pmid:21355891

    CrossRefPubMed
32. 32.↵
    2. Aldave G,
    3. Tejada S,
    4. Pay E, et al

    . Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery 2013;72:915–920; discussion 920–21 doi:10.1227/NEU.0b013e31828c3974 pmid:23685503

    CrossRefPubMed
33. 33.↵
    2. Lasocki A,
    3. Gaillard F

    . Non-contrast-enhancing tumor: a new frontier in glioblastoma research. AJNR Am J Neuroradiol 2019;40:758–65 doi:10.3174/ajnr.A6025 pmid:30948373

    Abstract/FREE Full Text
34. 34.↵
    2. Pope WB,
    3. Sayre J,
    4. Perlina A, et al

    . MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26:2466–74 pmid:16286386

    Abstract/FREE Full Text
35. 35.↵
    2. Jain R,
    3. Poisson LM,
    4. Gutman D, et al

    . Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology 2014;272:484–93 doi:10.1148/radiol.14131691 pmid:24646147

    CrossRefPubMed
36. 36.↵
    2. Kim R,
    3. Choi SH,
    4. Yun TJ, et al

    . Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. Eur Radiol 2017;27:1176–85 doi:10.1007/s00330-016-4464-6 pmid:27357131

    CrossRefPubMed
37. 37.↵
    2. Hwang I,
    3. Choi SH,
    4. Park CK, et al

    . Dynamic contrast-enhanced MR imaging of nonenhancing T2 high-signal-intensity lesions in baseline and posttreatment glioblastoma: temporal change and prognostic value. AJNR Am J Neuroradiol 2020;41:49–56 doi:10.3174/ajnr.A6323 pmid:31806595

    Abstract/FREE Full Text
38. 38.↵
    2. Kim C,
    3. Kim HS,
    4. Shim WH, et al

    . Recurrent glioblastoma: combination of high cerebral blood flow with MGMT promoter methylation is associated with benefit from low-dose temozolomide rechallenge at first recurrence. Radiology 2017;282:212–21 doi:10.1148/radiol.2016152152 pmid:27428890

    CrossRefPubMed
39. 39.↵
    2. Yoo RE,
    3. Choi SH,
    4. Kim TM, et al

    . Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. Eur Radiol 2017;27:3156–66 doi:10.1007/s00330-016-4692-9 pmid:27975145

    CrossRefPubMed
40. 40.↵
    2. Tolcher AW,
    3. Gerson SL,
    4. Denis L, et al

    . Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004–11 doi:10.1038/sj.bjc.6600827 pmid:12671695

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Birk HS,
    3. Han SJ,
    4. Butowski NA

    . Treatment options for recurrent high-grade gliomas. CNS Oncol 2017;6:61–70 doi:10.2217/cns-2016-0013 pmid:28001091

    CrossRefPubMed
42. 42.↵
    2. Taylor JW,
    3. Schiff D

    . Treatment considerations for MGMT-unmethylated glioblastoma. Curr Neurol Neurosci Rep 2015;15:507 doi:10.1007/s11910-014-0507-z pmid:25394859

    CrossRefPubMed
43. 43.↵
    2. Christmann M,
    3. Nagel G,
    4. Horn S, et al

    . MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer 2010;127:2106–18 doi:10.1002/ijc.25229 pmid:20131314

    CrossRefPubMedWeb of Science
44. 44.↵
    2. Della Puppa A,
    3. Persano L,
    4. Masi G, et al

    . MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients? J Neurooncol 2012;106:33–41 doi:10.1007/s11060-011-0639-9 pmid:21725802

    CrossRefPubMed
45. 45.↵
    2. Grasbon-Frodl EM,
    3. Kreth FW,
    4. Ruiter M, et al

    . Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 2007;121:2458–64 doi:10.1002/ijc.23020 pmid:17691113

    CrossRefPubMedWeb of Science